Solventum

Solventum is an American healthcare company created through the separation of 3M's healthcare business. Its activities originate in several healthcare-focused operations that 3M had developed across wound care, oral care, health informatics, and biopharmaceutical filtration. The company became a separate corporate entity on April 1, 2024, in a transaction intended to give the healthcare operations a more focused management structure and strategic identity independent of 3M's broader industrial portfolio. The separation was announced by 3M on July 26, 2022. The proposed company was designed to take responsibility for healthcare businesses whose combined sales represented approximately one quarter of 3M's total sales in 2021. The plan reflected a wider corporate strategy in which large diversified industrial groups separated healthcare or other major divisions into independent companies. 3M presented the move as a way to streamline operations and create greater strategic focus, while external observers associated it with changing economic conditions and pressure on the performance of diversified conglomerates. Before receiving its permanent name, the business was incorporated in Delaware on January 24, 2023, under the provisional name 3M Health Care Co. On November 16, 2023, 3M announced the name Solventum, formed from the concepts of solving problems and building momentum. Bryan Hanson became the company's first chief executive officer on September 1, 2023, ahead of the legal completion of the separation. Solventum's inherited portfolio covers products and services used by healthcare professionals, hospitals, laboratories, pharmaceutical manufacturers, and other healthcare organizations. Its wound-care activities include products intended to protect wounds, support healing, secure dressings, and assist clinical treatment. Its oral-care activities derive from 3M's dental and orthodontic businesses and include materials and systems used by dental professionals. Health informatics represents the company's software and technology-oriented healthcare activities, while biopharmaceutical filtration serves manufacturing and laboratory processes that require filtration and related separation technologies. The company is therefore positioned as a focused healthcare technology and solutions provider rather than a general industrial conglomerate. Its portfolio combines physical medical and dental products with software, clinical workflow capabilities, and process technologies used in biopharmaceutical production. The available references do not establish a headquarters address, official website, stock ticker, or complete list of operating markets, so those details are not stated in this entry. On February 25, 2025, Thermo Fisher Scientific was reported to have agreed to acquire Solventum's Purification & Filtration business for $4.1 billion. The proposed transaction would represent a further portfolio change following the separation from 3M, although the available sources do not provide completion details. Otherwise, Solventum remains an active healthcare company in the supplied references.

Solventum was created from the healthcare division of 3M. The separation was announced on July 26, 2022, as part of 3M's effort to simplify its structure and give its healthcare activities a dedicated corporate platform. The proposed company was to include 3M's wound-care, oral-care, health-informatics, and biopharmaceutical-filtration businesses. Together, these activities represented approximately one quarter of 3M's sales in 2021. The decision occurred during a period in which large diversified industrial companies were reassessing their portfolios and separating major divisions. Comparable restructuring activity included the planned creation of GE HealthCare, GE Aerospace, and GE Vernova, as well as the separation of Johnson & Johnson's consumer-health operations into Kenvue. In this context, 3M's healthcare spin-off was presented as a way to provide more focused management and allow the new company to pursue healthcare opportunities without being managed within 3M's wider mix of industrial and consumer businesses. The new healthcare company was incorporated in Delaware on January 24, 2023, under the temporary name 3M Health Care Co. Bryan Hanson was appointed its first chief executive officer effective September 1, 2023. On November 16, 2023, 3M disclosed the permanent name Solventum, a constructed name expressing the ideas of solving problems and generating momentum. The legal separation was completed on April 1, 2024. Solventum began operating as an independent healthcare company, while 3M retained approximately 19.9% of its shares. The inherited business portfolio spans clinical products used in wound management and dentistry, health information technology, and filtration systems used in biopharmaceutical production. This combination gives Solventum a mixed business model that includes medical consumables, professional healthcare products, software and informatics, and manufacturing-process technologies. After the separation, the company continued to review its portfolio. On February 25, 2025, Thermo Fisher Scientific was reported to have agreed to purchase Solventum's Purification & Filtration business for $4.1 billion. The available reference does not state whether the acquisition had closed, so the transaction is recorded as an announced or reported portfolio decision rather than a completed sale. No additional headquarters, ownership, listing, or operating-market information is established by the supplied sources.

• 2025

  Purification & Filtration sale announced

  [1]Solventumen.wikipedia.org

  Thermo Fisher Scientific was reported to have agreed to acquire Solventum's Purification & Filtration business for $4.1 billion.

• 2024

  Spin-off completed

  [1]Solventumen.wikipedia.org

  Solventum became an independent company on April 1, with 3M retaining approximately 19.9% ownership.

• 2023

  3M Health Care Co. is incorporated

  [1]Solventumen.wikipedia.org

  The future Solventum business was registered in Delaware under the provisional corporate name 3M Health Care Co.

• 2023

  Solventum name announced

  [1]Solventumen.wikipedia.org

  3M announced the permanent name Solventum for the healthcare company being separated from the parent.

• 2022

  3M announces healthcare separation

  [1]Solventumen.wikipedia.org

  3M announced that its healthcare division would be separated into a new company covering wound care, oral care, health informatics, and biopharmaceutical filtration.

A focused healthcare company combining clinical products, healthcare information technology, and biopharmaceutical process solutions.

• Medical products

  Wound care

  Solventum's wound-care activities originate in products developed within 3M's healthcare portfolio. They address clinical wound management and related needs such as protecting wounds, securing dressings, supporting treatment, and helping healthcare professionals manage patients in clinical settings. The supplied source identifies wound care as a principal business area but does not provide a detailed product catalogue.

• Dental and orthodontic products

  Oral care

  The oral-care business includes products and systems inherited from 3M's dental and orthodontic operations. These offerings serve dental professionals and may include materials, components, and clinical products used in restorative, preventive, and orthodontic workflows. The available reference confirms the business area but does not enumerate individual branded products.

• Healthcare information technology

  Health informatics

  Solventum's health-informatics activities represent the software and information-technology side of its portfolio. They are intended to support healthcare information, clinical workflows, and organizational decision-making. The supplied material identifies health informatics as part of the spun-off division without specifying individual platforms, customer segments, or current product names.

• Biopharmaceutical processing technology

  Purification & Filtration

  The Purification & Filtration business provides filtration-related technologies associated with biopharmaceutical manufacturing and laboratory processes. It was included in the original healthcare separation from 3M. In 2025, Thermo Fisher Scientific was reported to have agreed to acquire this business unit, but the supplied source does not confirm whether the transaction closed.

• 2025

  Agree to sell Purification & Filtration to Thermo FisherM&A

  Background

  Following the separation from 3M, Solventum was reported to have agreed to divest its Purification & Filtration business.

  Action taken

  Thermo Fisher Scientific was reported to have agreed to acquire the business unit for $4.1 billion.

  Aftermath

  The supplied reference does not establish whether the acquisition was completed or describe its operational consequences.

  Reported acquisition value. $4.1 billion (2025 announcement)

  Source

• 2023

  Adopt the Solventum corporate nameOther

  Background

  The healthcare company initially operated under the provisional name 3M Health Care Co. while preparations for the spin-off continued.

  Action taken

  3M announced Solventum as the permanent name, combining ideas associated with solving problems and creating momentum.

  Aftermath

  The name became the identity of the independent healthcare company at the completion of the spin-off.

  Source

• 2022

  Separate the healthcare division from 3MStrategy

  Background

  3M sought to streamline its portfolio and give its healthcare operations a more focused corporate structure. The planned company would contain wound care, oral care, health informatics, and biopharmaceutical filtration businesses.

  Action taken

  3M announced the creation of a separately operated healthcare company and subsequently prepared the business for legal separation.

  Aftermath

  The separation was completed on April 1, 2024, and 3M retained approximately 19.9% of Solventum.

  Source

1. 1Solventumen.wikipedia.org